The WHO has cleared the first child-friendly Artemether-Lumefantrine formulation for infants (2–5kg). This dual-action ACT therapy ensures precision dosing, eliminating risky manual adjustments and closing a critical treatment gap for the world's most vulnerable newborns.
Click to View More
© 2026 iasgyan. All right reserved